Evidence map›Paper›PMID 34326133›Full record

ArticleClinical cancer research : an official journal of the American Association for Cancer Research2021

Location of Gastrointestinal Stromal Tumor (GIST) in the Stomach Predicts Tumor Mutation Profile and Drug Sensitivity.

Ashwyn K Sharma, Jorge de la Torre, Nikki S IJzerman, Thomas L Sutton, Beiqun Zhao, Tahsin M Khan, Sudeep Banerjee, Christina Cui, Vi Nguyen, Maha Alkhuziem and 20 more

Open access · bronzeAbstract read
In one paragraph

Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed, 2 pooled it
4.0field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 2 syntheses or guidelines pooled it, 30 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Observational
  6. Review
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Review
  13. Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

30 authors at 6 institutions in 2 countries.

Ashwyn K Sharma *Department of Surgery, Division of Surgical Oncology, University of California San Diego, San Diego, California.
Jorge de la Torre *Department of Surgery, Division of Surgical Oncology, University of California San Diego, San Diego, California.
Nikki S IJzerman *Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands.ORCID 0000-0002-7473-6606
Thomas L SuttonDepartment of Surgery, Division of Surgical Oncology, Oregon Health and Science University, Knight Cancer Institute, Portland, Oregon.ORCID 0000-0002-2894-7154
Beiqun ZhaoDepartment of Surgery, Division of Surgical Oncology, University of California San Diego, San Diego, California.ORCID 0000-0003-2181-3783
Tahsin M KhanSurgical Oncology Program, Center for Cancer Research, NCI, NIH, Bethesda, Maryland.
Sudeep BanerjeeDepartment of Surgery, Division of Surgical Oncology, University of California San Diego, San Diego, California.
Christina CuiDepartment of Surgery, Division of Surgical Oncology, University of California San Diego, San Diego, California.ORCID 0000-0002-1525-8499
Vi NguyenDepartment of Surgery, Division of Surgical Oncology, University of California San Diego, San Diego, California.
Maha AlkhuziemDepartment of Surgery, Division of Surgical Oncology, University of California San Diego, San Diego, California.ORCID 0000-0002-3457-880X
Petur SnaebjornssonDepartment of Pathology, Netherlands Cancer Institute, Amsterdam, the Netherlands.ORCID 0000-0002-1086-8108
Hester van BovenDepartment of Pathology, Netherlands Cancer Institute, Amsterdam, the Netherlands.
Annemarie BruiningDepartment of Radiology, Netherlands Cancer Institute, Amsterdam, the Netherlands.
Chih-Min TangDepartment of Surgery, Division of Surgical Oncology, University of California San Diego, San Diego, California.
Hyunho YoonDepartment of Surgery, Division of Surgical Oncology, University of California San Diego, San Diego, California.
Alexa De la FuenteDepartment of Surgery, Division of Surgical Oncology, University of California San Diego, San Diego, California.
Shumei KatoMoores Cancer Center, University of California San Diego, La Jolla, California.
Hitendra PatelMoores Cancer Center, University of California San Diego, La Jolla, California.
Michael C HeinrichDepartment of Medical Oncology, Portland VA Health Care System and Oregon Health and Science University, Knight Cancer Institute, Portland, Oregon.ORCID 0000-0003-3790-0478
Christopher L CorlessDepartment of Pathology, Oregon Health and Science University, Knight Cancer Institute, Portland, Oregon.
Santiago HorganDepartment of Surgery, Division of Minimally Invasive Surgery, University of California San Diego, San Diego, California.
Adam M BurgoyneMoores Cancer Center, University of California San Diego, La Jolla, California.ORCID 0000-0002-4351-9940
Paul FantaMoores Cancer Center, University of California San Diego, La Jolla, California.
Jill P MesirovMoores Cancer Center, University of California San Diego, La Jolla, California.
Andrew M BlakelySurgical Oncology Program, Center for Cancer Research, NCI, NIH, Bethesda, Maryland.ORCID 0000-0002-5013-3851
Jeremy L DavisSurgical Oncology Program, Center for Cancer Research, NCI, NIH, Bethesda, Maryland.ORCID 0000-0002-6334-6936
Skye C MayoDepartment of Surgery, Division of Surgical Oncology, Oregon Health and Science University, Knight Cancer Institute, Portland, Oregon.ORCID 0000-0002-1631-9855
Winan J van HoudtDepartment of Surgical Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands.
Neeltje SteeghsDepartment of Medical Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands.
Jason K SicklickDepartment of Surgery, Division of Surgical Oncology, University of California San Diego, San Diego, California.
University of San Diego · USDutch Cancer Society · NLOregon Health & Science University · USUniversity of California San Diego · USCenter for Cancer Research · USOncode Institute · NL

Funding

UCSD Cancer Center Training Program in Drug DevelopmentT32CA121938 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Michael Bouvet, Dwayne G. Stupack · 2006 to 2026
$10.3M
GenePattern and GenePattern Notebook: Integrative 'Omic Analysis for Cancer ResearchU24CA248457 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI MESIROV, JILL P., TAMAYO, PABLO · 2020 to 2024
$4.6M
Embryonal Brain Tumor NetworksU01CA184898 · NCI · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI FRAENKEL, ERNEST, MESIROV, JILL P. · 2014 to 2019
$3.6M
Targeting Drug-Resistant Cancer Stem Cell Niches of Gastrointestinal Stromal TumorR01CA226803 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI SICKLICK, JASON KEITH · 2019 to 2023
$2.1M
BLRD VA I01 BX000338FDA HHS R01 FD006334NCI NIH HHS R01 CA226803NCI NIH HHS T32 CA121938NCI NIH HHS U01 CA184898NCI NIH HHS U24 CA248457
6 · The paper itself

Abstract

purposeGastrointestinal stromal tumors (GIST) commonly arise in different regions of the stomach and are driven by various mutations (most often in KIT, PDGFRA, and SDHx). We hypothesized that the anatomic location of gastric GIST is associated with unique genomic profiles and distinct driver mutations. EXPERIMENTAL

designWe compared KIT versus non-KIT status with tumor location within the National Cancer Database (NCDB) for 2,418 patients with primary gastric GIST. Additionally, we compiled an international cohort (TransAtlantic GIST Collaborative, TAGC) of 236 patients and reviewed sequencing results, cross-sectional imaging, and operative reports. Subgroup analyses were performed for tumors located proximally versus distally. Risk factors for KIT versus non-KIT tumors were identified using multivariate regression analysis. A random forest machine learning model was then developed to determine feature importance.

resultsWithin the NCDB cohort, non-KIT mutants dominated distal tumor locations (P < 0.03). Proximal GIST were almost exclusively KIT mutant (96%) in the TAGC cohort, whereas 100% of PDGFRA and SDH-mutant GIST occurred in the distal stomach. On multivariate regression analysis, tumor location was associated with KIT versus non-KIT mutations. Using random forest machine learning analysis, stomach location was the most important feature for predicting mutation status.

conclusionsWe provide the first evidence that the mutational landscape of gastric GIST is related to tumor location. Proximal gastric GIST are overwhelmingly KIT mutant, irrespective of morphology or age, whereas distal tumors display non-KIT genomic diversity. Anatomic location of gastric GIST may therefore provide immediate guidance for clinical treatment decisions and selective confirmatory genomic testing when resources are limited.

Indexed as

Gastrointestinal Stromal TumorsHumansMutationPrognosisProto-Oncogene Proteins c-kitReceptor, Platelet-Derived Growth Factor alphaStomachProto-Oncogene Proteins c-kitReceptor, Platelet-Derived Growth Factor alpha

Identifiers

PMID34326133
PMCPMC8799780
OpenAlexW3186652181

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.